6 results about "Cornea dystrophy" patented technology

The present application relates to the field of medicine, in particular to oligonucleotide, viral vector and its application and RNAi drug preparation. The oligonucleotide is one or two of the nucleic acid sequences shown in SEQ ID NO: 1 to SEQ ID NO: 7; or the oligonucleotide with the nucleic acid sequence of the above-mentioned oligonucleotide is not less than 80% consistent. The present application finds that the RNAi drug can significantly reduce the expression of mutant COL8A2, can treat the corneal dystrophy that has occurred, and can prevent the occurrence of corneal dystrophy. It can be seen that the RNAi drug preparation of the present application can effectively treat and prevent the corneal dystrophy caused by COL8A2 mutation.

The present invention provides an antisense oligonucleotide pharmaceutical composition for preventing or treating Avellino corneal dystrophy, which induces the suppression of R124H mutant TGFBI protein expression, its use, or a method for treating the same. In particular, the present invention selectively acts on R124H TGFBI mRNA, which is a precursor to the production of R124H mutant TGFBI protein, the causative protein of Avellino corneal dystrophy, thereby minimizing the effect on normal WT TGFBI expression and inducing the inhibition of R124H TGFBI expression, thereby enabling highly effective prevention or treatment of Avellino corneal dystrophy.

The present invention relates to compositions, systems, and methods for treating a subject with an eye condition (e.g., topically) using a composition comprising an ACE-2 receptor antagonist (also known as Angiotensin II Receptor Blocker or “ARB”) (e.g., losartan, telmisartan, valsartan, olmesartan, candesartan, irbesartan, eprosartan, azilsartan, or losartan metabolite EXP3174). In certain embodiments, the eye condition is selected from: i) a corneal scarring fibrosis, ii) a transforming growth factor beta-induced (TGFBI) corneal dystrophy, iii) a conjunctival fibrotic disease, iv) an intraocular fibrotic disease, and v) a conjunctival bleb scarring and / or shunt encapsulation (e.g., following glaucoma surgery).

The present invention relates to an oil-in-water microemulsion that has shown to be a suitable drug depot system for the treatment of disorders of the anterior segment of the eye, wherein said disease is selected from the group consisting of corneal neovascularization disease (NV), ocular melanoma, Gelatinous drop-like corneal dystrophy (GDLD), Secondary corneal amyloidosis—GDLD type, Graves ophthalmopathy, Stevens-Johnson syndrome (SJS), Mooren's ulcer, and Corneal graft rejection and more particularly of neovascularization disease (NV). The microemulsion according to the invention is indeed capable of effectively delivering and maintaining on the anterior segment of the eye high concentrations of active ingredients after administration.

The present invention relates to: a pharmaceutical composition of an antisense oligonucleotide, which induces inhibition of the expression of an R124H mutant of a TGFBI protein for the prevention or treatment of Avellino corneal dystrophy; a use of the composition; or methods of treatment thereof. In particular, the present invention selectively acts on R124H TGFBI mRNA (R124H TGFBI mRNA is a precursor of R124H TGFBI protein causing Avellino corneal dystrophy), thereby inducing inhibition of R124H TGFBI expression while minimizing the effect on WT TGFBI expression, and thus can very effectively prevent or treat Avellino corneal dystrophy.

Provided are methods of treating or preventing corneal endothelial disease. The present disclosure relates to corneal endothelial cell compositions comprising cultured human corneal endothelial cells and a Rho-associated, coiled-coil containing protein kinase inhibitor, and uses of the compositions for the treatment of corneal endothelial diseases, including bullous keratopathy, corneal edema, corneal leukoma, corneal endothelial inflammation, and corneal dystrophy.